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Background: The ABS device is a modular, dual-catheter, independently movable delivery system (7f) consisting of a mother-daughter stent 
(MD) on an over-the-wire balloon catheter, a daughter stent (DS) on a monorail catheter. The DS catheter is loaded on a sleeve of the MD catheter 
and protrudes through an opening in the middle of the MD stent leading the system. The DS delivery balloon is twice the length of the DS which is 
mounted on the distal half of it.
Methods: The system is loaded on 2 wires and advanced to the carina. The leading DS catheter is then pulled back into the MD stent and the 
proximal markers of the two balloons are aligned. The bifurcation stent is now assembled at the carina. The DS balloon is inflated first and partially 
deploys and rotates the proximal segment of the MD to align with the daughter vessel automatically. It simultaneously deploys the DS. The MD 
balloon is inflated to deploy the MD stent. Kissing balloon inflation fully deploys the system.
Patients with de novo bifurcation lesions were enrolled in this pilot, non-randomized, multi-center trial evaluating the safety, technical feasibility, and 
acute efficacy of the ABS Stent System. The primary endpoint is 30-day composite MACE (death, MI, and target vessel revascularization). The ABS 
stent was implanted in the following bifurcation: LAD-Diag (2), LCx-OM (3), PDA-PLB (2). All were Medina 1,1,1. Secondary endpoints are procedural 
success and safety at 6 months as well as 6 month agiographic.
Results: The 30-day composite MACE was 0%. Procedural success was 100%, and there was no residual stenosis by IVUS, which revealed full stent 
apposition with complete coverage of the vessel carina.
6 month composite MACE as well as TVR has remained 0%. All patients are free of angina. Aniographic follow-up to date has revealed edge restenosis 
in 2 side-branch vessels only.
Conclusions: The ABS Bifurcation Stent Delivery System is a novel stent platform designed to reproducibly permit stenting in bifurcation lesions 
regardless of branch angulation. This first-in-human implant study provides preliminary evidence of feasibility and short-term efficacy. Additional 
long-term and larger scale studies are needed to further validate this unique device.
